Haiart Sebastien, Watson David I, Leong Mary P, Astill David, Bright Tim, Hussey Damian J
Department of Surgery, Flinders University, Flinders Medical Centre, Room 3D211, Bedford Park, South Australia 5042, Australia.
BMC Res Notes. 2011 Feb 27;4:41. doi: 10.1186/1756-0500-4-41.
Proton pump inhibitor (PPI) medication and surgical fundoplication are used for the control of gastro-oesophageal reflux in patients with Barrett's oesophagus, but differ in their effectiveness for both acid and bile reflux. This might impact on the inflammatory processes that are associated with progression of Barrett's oesophagus to cancer, and this may be evident in the gene expression profile and microRNA expression pattern in Barrett's oesophagus mucosa. We hypothesised that two miRNAs with inflammatory and oncogenic roles, miR-101 and miR-196a, are differentially expressed in Barrett's oesophagus epithelium in patients with reflux treated medically vs. surgically.
Mucosal tissue was obtained at endoscopy from patients with Barrett's oesophagus whose reflux was controlled by proton pump inhibitor (PPI) therapy (n = 20) or by fundoplication (n = 19). RNA was extracted and the expression of miR-101 and miR-196a was measured using real-time reverse transcription - polymerase chain reaction. There were no significant differences in miR-101 and miR-196a expression in Barrett's oesophagus epithelium in patients treated by PPI vs. fundoplication (p = 0.768 and 0.211 respectively). Secondary analysis showed a correlation between miR-196a expression and Barrett's oesophagus segment length (p = 0.014).
The method of reflux treatment did not influence the expression of miR-101 and miR-196a in Barrett's oesophagus. This data does not provide support to the hypothesis that surgical treatment of reflux better prevents cancer development in Barrett's oesophagus. The association between miR-196a expression and Barrett's oesophagus length is consistent with a tumour promoting role for miR-196a in Barrett's oesophagus.
质子泵抑制剂（PPI）药物治疗和手术性胃底折叠术用于控制巴雷特食管患者的胃食管反流，但在控制酸反流和胆汁反流的效果上有所不同。这可能会影响与巴雷特食管进展为癌症相关的炎症过程，并且这可能在巴雷特食管黏膜的基因表达谱和微小RNA表达模式中表现明显。我们推测，具有炎症和致癌作用的两种微小RNA，即miR-101和miR-196a，在接受药物治疗与手术治疗的反流性巴雷特食管患者的食管上皮中表达存在差异。
通过内镜检查从反流通过质子泵抑制剂（PPI）治疗（n = 20）或胃底折叠术（n = 19）得到控制的巴雷特食管患者获取黏膜组织。提取RNA，并使用实时逆转录-聚合酶链反应测量miR-101和miR-196a的表达。在接受PPI治疗与胃底折叠术治疗的患者的巴雷特食管上皮中，miR-101和miR-196a表达无显著差异（分别为p = 0.768和0.211）。二次分析显示miR-196a表达与巴雷特食管段长度之间存在相关性（p = 0.014）。
反流治疗方法不影响巴雷特食管中miR-101和miR-196a的表达。该数据不支持手术治疗反流能更好地预防巴雷特食管癌症发生这一假说。miR-196a表达与巴雷特食管长度之间的关联与miR-196a在巴雷特食管中的促肿瘤作用一致。
